Recruiting studies: Stage Iva Prostate Cancer Ajcc V8

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT04734730 Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Phase 3 · 338 location(s) · SWOG Cancer Research Network · NCT03678025 Vitamin D for Prostate Endocrine Therapy
Phase 3 · 51 location(s) · University of Rochester · NCT05838716 Nutrition and Exercise Interventions for Androgen Deprivation Therapy-Induced Obese Frailty in Elderly and Non-Elderly S
NA · 1 location(s) · Roswell Park Cancer Institute · NCT03880422 Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME T
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT04693377 High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma
NA · 1 location(s) · Jonsson Comprehensive Cancer Center · NCT04945642 Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Can
Phase 1 · 1 location(s) · Jonsson Comprehensive Cancer Center · NCT05398302 REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
Phase 3 · 4 location(s) · Emory University · NCT06650579 Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04947254 Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer
NA · 1 location(s) · Mayo Clinic · NCT06389786 Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modificatio
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05054296 Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Phase 2 · 1 location(s) · University of Utah · NCT05168618 Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Phase 1/Phase 2 · 1 location(s) · Vadim S Koshkin · NCT05113537 Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Phase 3 · 413 location(s) · NRG Oncology · NCT05946213

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.